Skip to main navigation menu Skip to main content Skip to site footer
FrancoAngeli Journals

Saggi, Studi e Ricerche

No. 60 (2022)

Diagnostic and Therapeutic Path (PDTA) for people using drugs and alcohol referred to the addictive behaviour centres and for the prison population

DOI
https://doi.org/10.3280/mis60-2022oa15188
Submitted
gennaio 19, 2023
Published
2023-06-09

Abstract

The article presents the final document of a working group made up of all the directors/managers of the Addictive Behaviour Centres (SerD) of the Lombardy Region coordinated by the authors

The final product declines the Diagnostic and Therapeutic Path (PDTA) for people using drugs and alcohol referred to the addictive behaviour centres and for the prison population.

Four main elements were considered when designing the PDTA:

  1. The ideal path represented by the Point of Care Model which allows diagnosis and treatment in places of access for patients, favouring both an easy screening of the hidden population and the early treatment of HCV infection.
  2. The variable epidemiological context in relation to the area in which a service operates (metropolitan area, big cities, mountain areas, etc.).
  3. The prevalence of the population that refers to the individual services (intravenous or other routes users, people with high risk alcohol consumption, etc.).
  4. The organizational contexts by evaluating the most important critical element linked to the lack of personnel of the SerD and the Penitentiary Health.

For this reason, the PDTA provides a basic and an advanced path and are applicable in any organizational context.

References

  1. Aghemo A., Lampertico P., Colombo M. (2012). Assessing longterm treatment effi cacy in chronic hepatitis B and C: between evidence and common sense. J Hepatol., 57(6): 1326-35. DOI: 10.1016/j.jhep.2012.06.025.
  2. AISF Associazione Italiana per lo Studio del Fegato (2020). Documento di indirizzo dell’Associazione Italiana per lo Studio del Fegato per l’uso razionale dei farmaci anti-HCV disponibili in Italia. Aggiornamento del 14 dicembre.
  3. Andriulli A., Stroffolini T., Mariano A., Valvano M.R., Grattagliano I., Ippolito A.M., Grossi A., Brancaccio G., Coco C., Russello M., Smedile A., Petrini E., Martini S., Gaeta G.B., Rizzetto M. (2018). Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in fi ve metropolitan areas. Eur J Intern Med., 53: 79-84. DOI: 10.1016/j.ejim.2018.02.015.
  4. The Polaris Observatory HCV Collaborators (2022). Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol, published online Feb 15. DOI: 10.1016/S2468-1253(21)00472-6.
  5. European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol., 73(5): 1170-1218. DOI: 10.1016/j.jhep.2020.08.018.
  6. Gardini I., Bartoli M., Conforti M., Mennini F.S., Marcellusi A. (2019). Estimation of the number of HCVpositive patients in Italy. PLoS One, Oct 31, 14(10): e0223668. DOI: 10.1371/journal.pone.0223668.
  7. Kondili L.A., Andreoni M., Alberti A., Lobello S., Babudieri S., Roscini A.S., Merolla R., Marrocco W., Craxì A. (2021). Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. Epidemics, Mar, 34: 100442. DOI: 10.1016/j.epidem.2021.100442.
  8. WHO (2018). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. July.
  9. Fiore V., De Matteis G., Ranieri R., Saderi L., Pontali E., Muredda A. et al. (2021). HCV testing and treatment initiation in an Italian prison setting: a step-by-step model to micro-eliminate hepatitis C. Int J Drug Policy, 90, 103055. DOI: 10.1016/j.drugpo.2020.103055.

Metrics

Metrics Loading ...